Repligen Corporation to Report Q4 2025 Financial Results on February 24, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy RGEN?
Source: Newsfilter
- Earnings Release Schedule: Repligen Corporation will report its Q4 2025 financial results on February 24, 2026, with a press release expected before market open, providing investors with timely financial updates and business insights.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET, allowing domestic callers to dial toll-free (800) 715-9871 and international callers to use (646) 307-1963, facilitating investor engagement and detailed discussions on financial results.
- Webcast Access: Investors can access the conference call via a webcast on the company's Investor Relations section, ensuring global investors can receive real-time critical information, thereby enhancing transparency and communication.
- Company Overview: Repligen is a global life sciences company focused on developing and commercializing bioprocessing technologies that serve biopharmaceutical developers and contract development manufacturing organizations, showcasing its innovative capabilities and market impact in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGEN
Wall Street analysts forecast RGEN stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 118.210
Low
165.00
Averages
189.00
High
207.00
Current: 118.210
Low
165.00
Averages
189.00
High
207.00
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Repligen Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Repligen reported $194 million in revenue for Q1, reflecting a 15% year-over-year increase with 11% organic growth, indicating strong performance in the biopharmaceutical market that is expected to enhance future market share.
- Earnings Guidance Raised: The management has increased the full-year adjusted earnings per share guidance to between $1.97 and $2.05, reflecting confidence in the company's profitability while indicating that the divestiture of low-margin operations will improve overall financial health.
- Expansion in China: The company signed a critical OEM partnership to begin local manufacturing in China in 2027, which will not only enhance its presence in the Chinese market but also lay the groundwork for future revenue growth.
- Transformation Office Established: Repligen has formed a transformation office aimed at achieving a 30% adjusted EBITDA margin by 2030, with an expected annualized margin benefit of at least 1 percentage point by the end of 2027, demonstrating the company's commitment to long-term profitability.
See More
Repligen (RGEN) Q1 2026 Earnings Call Transcript
See More
Repligen Q1 Earnings Announcement Scheduled
- Earnings Release Date: Repligen (RGEN) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of $0.38, reflecting a 2.6% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The expected revenue for Q1 is $192.17 million, representing a 13.7% year-over-year increase, indicating the company's growth potential in the market despite some pressure on profitability.
- Historical Performance: Over the past two years, Repligen has beaten EPS and revenue estimates 75% of the time, suggesting a level of stability and reliability in financial performance that may attract more investor interest.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and 13 downward revisions, while revenue estimates have experienced seven upward and six downward revisions, reflecting market divergence and uncertainty regarding the company's future performance.
See More
Next Week's Earnings Season to Feature Multiple Companies
- Earnings Surprises Expected: Next week, 121 companies, including Repligen and HubSpot, are set to report earnings, with expectations that these firms will exceed Wall Street forecasts, potentially driving stock price increases and reflecting market optimism about their performance.
- Strong Performance from Repligen: Repligen is expected to report earnings next Tuesday, with an average stock price increase of 3.1% following each report; Rothschild & Co. Redburn has initiated coverage with a buy rating and a price target of $160, implying a 41% upside from current levels.
- HubSpot's Recovery Potential: HubSpot will report earnings next Thursday, with an average stock price increase of 3.1% post-earnings; Bank of America has resumed coverage with a buy rating and a $300 price objective, suggesting a 32% upside, indicating market confidence in its future growth.
- Market Focus on Major Players: The earnings season will also feature well-known companies like Disney and McDonald's, expected to attract significant investor attention, particularly in the performance of sectors such as restaurants, media, and gig economy platforms.
See More
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
Repligen Opens New Training & Innovation Center in Breda, Netherlands
- Innovation Center Launch: Repligen has opened a new Training & Innovation Center in Breda, Netherlands, aimed at enhancing the company's technical capabilities in the biopharmaceutical sector by providing advanced training facilities to support client product development needs.
- Market Responsiveness Improvement: The establishment of this center will enable Repligen to better respond to the demands of the European market, particularly in the growing need for technical support and training in the biopharmaceutical industry, further solidifying its market position.
- Strategic Investment Focus: This investment not only demonstrates Repligen's commitment to the European market but also indicates the company's dedication to driving business growth through innovation and technical support, thereby strengthening customer relationships.
- Future Growth Potential: The new center is expected to create more collaboration opportunities for Repligen, especially in partnering with biopharmaceutical companies to develop new products and technologies, aiding the company's long-term development in the industry.
See More
Repligen Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Repligen reported $194 million in revenue for Q1, reflecting a 15% year-over-year increase with 11% organic growth, indicating strong performance in the biopharmaceutical market that is expected to enhance future market share.
- Earnings Guidance Raised: The management has increased the full-year adjusted earnings per share guidance to between $1.97 and $2.05, reflecting confidence in the company's profitability while indicating that the divestiture of low-margin operations will improve overall financial health.
- Expansion in China: The company signed a critical OEM partnership to begin local manufacturing in China in 2027, which will not only enhance its presence in the Chinese market but also lay the groundwork for future revenue growth.
- Transformation Office Established: Repligen has formed a transformation office aimed at achieving a 30% adjusted EBITDA margin by 2030, with an expected annualized margin benefit of at least 1 percentage point by the end of 2027, demonstrating the company's commitment to long-term profitability.
See More
Repligen (RGEN) Q1 2026 Earnings Call Transcript
See More
Repligen Q1 Earnings Announcement Scheduled
- Earnings Release Date: Repligen (RGEN) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of $0.38, reflecting a 2.6% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The expected revenue for Q1 is $192.17 million, representing a 13.7% year-over-year increase, indicating the company's growth potential in the market despite some pressure on profitability.
- Historical Performance: Over the past two years, Repligen has beaten EPS and revenue estimates 75% of the time, suggesting a level of stability and reliability in financial performance that may attract more investor interest.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and 13 downward revisions, while revenue estimates have experienced seven upward and six downward revisions, reflecting market divergence and uncertainty regarding the company's future performance.
See More
Next Week's Earnings Season to Feature Multiple Companies
- Earnings Surprises Expected: Next week, 121 companies, including Repligen and HubSpot, are set to report earnings, with expectations that these firms will exceed Wall Street forecasts, potentially driving stock price increases and reflecting market optimism about their performance.
- Strong Performance from Repligen: Repligen is expected to report earnings next Tuesday, with an average stock price increase of 3.1% following each report; Rothschild & Co. Redburn has initiated coverage with a buy rating and a price target of $160, implying a 41% upside from current levels.
- HubSpot's Recovery Potential: HubSpot will report earnings next Thursday, with an average stock price increase of 3.1% post-earnings; Bank of America has resumed coverage with a buy rating and a $300 price objective, suggesting a 32% upside, indicating market confidence in its future growth.
- Market Focus on Major Players: The earnings season will also feature well-known companies like Disney and McDonald's, expected to attract significant investor attention, particularly in the performance of sectors such as restaurants, media, and gig economy platforms.
See More
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
Repligen Opens New Training & Innovation Center in Breda, Netherlands
- Innovation Center Launch: Repligen has opened a new Training & Innovation Center in Breda, Netherlands, aimed at enhancing the company's technical capabilities in the biopharmaceutical sector by providing advanced training facilities to support client product development needs.
- Market Responsiveness Improvement: The establishment of this center will enable Repligen to better respond to the demands of the European market, particularly in the growing need for technical support and training in the biopharmaceutical industry, further solidifying its market position.
- Strategic Investment Focus: This investment not only demonstrates Repligen's commitment to the European market but also indicates the company's dedication to driving business growth through innovation and technical support, thereby strengthening customer relationships.
- Future Growth Potential: The new center is expected to create more collaboration opportunities for Repligen, especially in partnering with biopharmaceutical companies to develop new products and technologies, aiding the company's long-term development in the industry.
See More
